Australian Meningococcal Surveillance Programme annual report, 2014

Authors

  • Monica M Lahra WHO Collaborating Centre for STD and Neisseria Reference Laboratory, Microbiology Department, South Eastern Area Laboratory Services, Prince of Wales Hospital, Sydney, New South Wales; Schhool of Medical Sciences, University of New South Wales, Sydney, New South Wales
  • Rodney P Enriquez WHO Collaborating Centre for STD and Neisseria Reference Laboratory, Microbiology Department, South Eastern Area Laboratory Services, Prince of Wales Hospital, Sydney, New South Wales

DOI:

https://doi.org/10.33321/cdi.2016.40.17

Keywords:

antibiotic resistance, disease surveillance, meningococcal disease, Neisseria meningitidis

Abstract

In 2014 there were 165 laboratory-confirmed cases of invasive meningococcal disease analysed by the Australian National Neisseria Network. This number was higher than the number reported in 2013, but was the second lowest reported since inception of the Australian Meningococcal Surveillance Programme in 1994. Probable and laboratory confirmed invasive meningococcal disease (IMD) are notifiable in Australia, and there were 170 IMD cases notified to the National Notifiable Diseases Surveillance System (NNDSS) in 2014. This was also higher than in 2013, but was the second lowest number of IMD cases reported to the NNDSS. The meningococcal serogroup was determined for 161/165 (98%) of laboratory confirmed IMD cases. Of these, 80.1% (129 cases) were serogroup B infections; 1.9% (3 cases) were serogroup C infections; 9.9% (16 cases) were serogroup W135; and 8.1% (13 cases) were serogroup Y. Primary and secondary disease peaks were observed in those aged 4 years or less, and in adolescents (15–19 years) respectively. Serogroup B cases predominated in all jurisdictions and age groups, except for those aged 65 years or over, where serogroups Y and W135 combined predominated. The overall proportion and number of IMD caused by serogroup B was higher than in 2013, but has decreased from previous years. The number of cases of IMD caused by serogroup C was the lowest reported to date. The number of IMD cases caused by serogroup Y was similar to previous years, but the number of IMD cases caused serogroup W135 was higher than in 2013. The proportion of IMD cases caused by serogroups Y and W135 has increased in recent years, whilst the overall number of cases of IMD has decreased. Molecular typing was able to be performed on 106 of the 165 IMD cases. In 2014, the most common porA genotypes circulating in Australia were P1.7-2,4 and P1.22,14. All IMD isolates tested were susceptible to ceftriaxone and ciprofloxacin. There were 2 isolates that were resistant to rifampicin. Decreased susceptibility to penicillin was observed in 88% of isolates. Commun Dis Intell 2016;40(2):E221–E228.

Downloads

Download data is not yet available.

References

National Neisseria Network. Meningococcal Isolate Surveillance Australia, 1994. Commun Dis Intell 1995;19(12):286–289.

National Notifiable Diseases Surveillance System. Number of notifications of Meningococcal disease (invasive), received from State and Territory health authorities in the period of 1991 to 2012 and year-to-date notifications for 2014. [online] Accessed 2014. Available from: http://www9.health.gov.au/cda/source/cda-index.cfm

Public Health Laboratory Network. Meningococcal laboratory case definition. [online] Accessed 2014. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-phlncd-mening.htm

Tapsall J and members of the National Neisseria Network of Australia. Antimicrobial testing and applications in the pathogenic Neisseria. In: Merlino J, ed. Antimicrobial susceptibility testing: methods and practices with an Australian perspective. Sydney: Australian Society for Microbiology; 2004. p. 175–188.

Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197(5):737–743.

Australian Government Department of Health. Meningococcal Disease. Immunise Australia Program. [online] Accessed 2015. Available from: http://www1.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-meningococcal

Downloads

Published

01/06/16

How to Cite

Lahra, Monica M, and Rodney P Enriquez. 2016. “Australian Meningococcal Surveillance Programme Annual Report, 2014”. Communicable Diseases Intelligence 40 (June):221-28. https://doi.org/10.33321/cdi.2016.40.17.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>